Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, B152TT, UK.
Department of Pathology, University Hospital Birmingham, Birmingham, UK.
Cancer Immunol Immunother. 2022 Jul;71(7):1583-1596. doi: 10.1007/s00262-021-03081-5. Epub 2021 Nov 2.
Monocytic myeloid-derived suppressor cells (M-MDSCs) are significantly expanded in the blood of colorectal cancer (CRC) patients. However, their presence and underlying mechanisms in the tumour microenvironment of CRC have not been examined in detail.
Tumour tissues and peripheral blood from CRC patients were analysed for the presence of M-MDSCs. The mechanisms of suppression were analysed by blocking pathways by which MDSCs abrogate T cell proliferation. Co-culture of CRC cells with monocytes were performed with and without cytokine blocking antibodies to determine the mechanism by which CRC cells polarise monocytes. Multi-spectral IHC was used to demonstrate the intra-tumoral location of M-MDSCs.
Tumour tissues and blood of CRC patients contain M-MDSCs which inhibit T cell proliferation. Whilst inhibition of arginase and nitric oxide synthase 2 fail to rescue T cell proliferation, blockade of IL-10 released by these HLA-DR cells abrogates the suppresivity of M-MDSCs. Tumour conditioned media (TCM) significantly reduces HLA-DR expression, increases IL-10 release from monocytes and causes them to become suppressive. TGF-β is highly expressed in the TCM and accumulates in the plasma. TGF-β reduces HLA-DR expression and drives monocyte immunosuppressivity. The invasive margin of CRC is enriched in CD14 HLA-DR cells in close proximity to T cells.
Our study demonstrates the cross-talk between CRC cells, M-MDSCs and T cells. Characterisation of CRC M-MDSCs point to therapeutic avenues to target these cells in addition to TGF-β blockade.
单核细胞来源的髓系抑制细胞(M-MDSC)在结直肠癌(CRC)患者的血液中显著扩增。然而,它们在 CRC 肿瘤微环境中的存在及其潜在机制尚未被详细研究。
分析 CRC 患者的肿瘤组织和外周血中是否存在 M-MDSC。通过阻断 MDSC 抑制 T 细胞增殖的途径来分析抑制机制。与用细胞因子阻断抗体进行共培养,以确定 CRC 细胞使单核细胞极化的机制。多光谱免疫组化用于证明 M-MDSC 的肿瘤内位置。
CRC 患者的肿瘤组织和血液中含有抑制 T 细胞增殖的 M-MDSC。虽然抑制精氨酸酶和一氧化氮合酶 2 不能挽救 T 细胞增殖,但阻断这些 HLA-DR 细胞释放的 IL-10 可消除 M-MDSC 的抑制作用。肿瘤条件培养基(TCM)显著降低 HLA-DR 表达,增加单核细胞释放的 IL-10,并使其具有抑制作用。TCM 中 TGF-β 高度表达并在血浆中积累。TGF-β 降低 HLA-DR 表达并促使单核细胞免疫抑制。CRC 的侵袭性边缘富含 CD14 HLA-DR 细胞,与 T 细胞紧密相邻。
我们的研究证明了 CRC 细胞、M-MDSC 和 T 细胞之间的串扰。CRC M-MDSC 的特征表明,除了 TGF-β 阻断外,还可以靶向这些细胞进行治疗。